Brief: Abionyx Receives Positive Opinion On ODD Application For CER-001

Abionyx Pharma SA

28/07/2021 06:39

July 28 (Reuters) - ABIONYX PHARMA SA  ABNX.PA :
    * ABIONYX PHARMA RECEIVES POSITIVE OPINION FROM EMA WITHIN
THE
FRAMEWORK OF THE ORPHAN DRUG DESIGNATION PROCESS FOR CER-001 FOR
THE RARE DISEASE LCAT DEFICIENCY
    * CULMINATION OF NEW STRATEGY IN AN ULTRA-RARE KIDNEY
DISEASE
    * NEW STEP IN REPOSITIONING PRODUCT FOR RENAL AND
OPHTHALMOLOGIC
DISEASES
    * SECURED BIOMANUFACTURING OF CER-001 FOR FUTURE TRIALS

Source text for Eikon:  ID:nBw2Vlmzwa 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))